A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL)

Hoffmann La Roche0 个研究点目标入组 682 人开始时间: 2021年10月22日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC
•-Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
•-Measurable disease
•-Adequate recovery from most recent systemic or local treatment for cancer
•-Adequate organ function
•-Life expectancy greater than or equal to (>/=) 12 weeks
•-For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception

•-Inability to swallow oral medication
•-Women who are pregnant or lactating
•-Symptomatic, untreated CNS metastases
•-History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death
•-Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina
•-Known human immunodeficiency virus (HIV) positivity or autoimmune deficiency syndrome (AIDS)-related illness
•-Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study
•-Inability to comply with other requirements of the protocol

发起方